Brief: Roquefort Therapeutics Extends AO-252 License Agreement To 16 March 2026

Coiled Therapeutics

12/12/2025 07:27

Dec 12 (Reuters) - Roquefort Therapeutics PLC ROQ.L:

ROQUEFORT THERAPTCS.  - CLINICAL TRIAL & LICENSE AGREEMENT UPDATE

ROQUEFORT THERAPEUTICS PLC - EXTENDS AO-252 LICENSE AGREEMENT TO 16 MARCH 2026

ROQUEFORT THERAPEUTICS PLC - UPFRONT CONSIDERATION FOR AO-252 LICENSE INCREASED TO £31,875,000

Source text: ID:nRSL2919La

Further company coverage: ROQ.L

 ((Reuters.Briefs@thomsonreuters.com;))